Work

252P Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience

Year: 2022

Type: article

Study design: Observational Study

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2022.07.291

Authors: C. Labaki, Z. Bakouny, T. Sanglier, A. Schmidt, J. Shim, D.A. Braun, F. Bouquet, M. Joyce, W. Xie, S.M. Tolaney, T.K. Choueiri

Institutions: Dana-Farber Cancer Institute, F. Hoffmann-La Roche AG, Yale Cancer Center, Yale University, Roche (France)

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4295817418

FWCI: 0.251

Cites:

Cited by: 3

Related to: 10